MK-677 (Ibutamoren) + AOD-9604 Stack: Evidence, Mechanism, and What Women Should Know

What Are MK-677 and AOD-9604, Exactly?

MK-677 (generic name ibutamoren) is a non-peptide ghrelin receptor agonist. It is taken orally, which separates it mechanically from most peptides. It binds the growth hormone secretagogue receptor 1a (GHSR-1a) and triggers the pituitary to release growth hormone (GH) in a pulsatile pattern that mimics the natural overnight surge. In a 52-week randomized trial in older adults, MK-677 raised serum IGF-1 by roughly 40% and GH area-under-curve by 97% without suppressing endogenous production.

AOD-9604 is a synthetic 16-amino-acid fragment corresponding to positions 176 to 191 on the C-terminus of human growth hormone. The fragment contains the region researchers believed drives lipolytic activity while omitting the IGF-1-stimulating N-terminal domain. Its developer, Metabolic Pharmaceuticals, advanced it through Phase IIb trials for obesity before the program was discontinued. Current AOD-9604 on the market is sold as a research chemical; it holds no approved human-use indication anywhere in the world.

Why Women Search This Stack

Body composition shifts accelerate during perimenopause. Visceral fat accumulates even when caloric intake is stable, partly because GH pulse amplitude drops by around 50% between age 25 and 55 in women. That physiology drives interest in compounds that restore GH signaling or directly stimulate fat mobilization. Women in online peptide communities frequently report pairing MK-677 (for its overnight GH lift and potential lean-mass support) with AOD-9604 (for targeted lipolysis).

A Plain-Language Mechanism Comparison

| Property | MK-677 (Ibutamoren) | AOD-9604 | |---|---|---| | Route | Oral capsule or liquid | Subcutaneous injection | | Primary target | GHSR-1a (ghrelin receptor) | Beta-3 adrenergic receptor (proposed) and lipid metabolism pathways | | IGF-1 effect | Raises IGF-1 significantly | Minimal to no IGF-1 effect in animal studies | | GH effect | Stimulates pulsatile GH release | Does not raise GH appreciably | | Insulin sensitivity | May worsen in susceptible women | Appears neutral to mildly positive in rodent models | | Evidence level | Multiple human RCTs (separate indications) | Phase IIb human trial; mixed results |

How the Two Compounds Are Thought to Overlap

The theoretical rationale for stacking them is complementarity, not redundancy. MK-677 restores GH pulsatility and raises IGF-1, which supports lean tissue and bone turnover. AOD-9604 is intended to activate lipolysis through a GH-independent pathway, meaning it may work on adipose tissue without the insulin-disrupting IGF-1 rise that comes with full-length GH administration.

In rodent studies, AOD-9604 reduced fat mass without affecting IGF-1 or blood glucose at doses equivalent to 250-500 mcg/day in humans. That separation of lipolytic from growth-promoting activity is the biological premise for pairing it with a GH secretagogue.

Where the Evidence Gets Thin

The critical gap: no published study has tested this combination in humans. Every claim about stack combination comes from one of three sources: extrapolation from separate single-compound data, rodent models, or practitioner and community observation. Each source carries real limitations.

The Phase IIb trial of AOD-9604 (the METAOD study, NCT00074165) enrolled adults with obesity and found no statistically significant weight loss difference versus placebo at 24 weeks across most dose arms. The 1 mg/day arm showed a modest signal, but the program was not advanced to Phase III. That result is frequently under-reported in peptide marketing materials.

MK-677 human trials are more encouraging for specific endpoints. The GHRES trial showed lean body mass gains of 1.6 kg over 12 months in older adults, and a separate 12-month trial in GH-deficient adults showed reduced fat mass alongside raised IGF-1. But these trials used MK-677 as monotherapy, enrolled both sexes without sex-stratified reporting, and were conducted in populations with documented GH deficiency, not healthy women seeking body recomposition.

The WomanRx editorial team applies a four-tier evidence framework to peptide stacks. Tier 1 is human RCT data for the specific stack in women. Tier 2 is human RCT data for each compound separately, with some female-participant data available. Tier 3 is animal or mechanistic data only. Tier 4 is community and practitioner observation with no controlled data. The MK-677 plus AOD-9604 stack sits at Tier 2 for MK-677 alone, Tier 3 for AOD-9604 alone, and Tier 4 for the combination itself. Any clinician or platform rating this stack higher is overstating the evidence.

Sex-Specific Physiology: Why Women Are Not Just Smaller Men

Women's GH physiology differs from men's in ways that matter for dosing and risk. At baseline, women have higher GH pulse amplitude but faster clearance, producing a different 24-hour GH exposure profile. Estrogen increases GH secretion at the hypothalamic level; as estrogen falls in perimenopause and postmenopause, that amplification is lost. MK-677 partially compensates by acting directly at the pituitary, which is one reason perimenopausal women report noticing its effects acutely.

Menstrual Cycle Effects

No published data characterizes how MK-677 interacts with menstrual cycle phase. GH pulsatility naturally peaks in the luteal phase. Women in the peptide community report that MK-677 side effects, particularly water retention and hunger, feel worse in the luteal phase, consistent with the additive effect on an already-elevated GH baseline. This is practitioner-level observation, not controlled data.

AOD-9604 has no published data on menstrual cycle interaction. Given that it does not appear to affect sex hormones in rodent models, cycle-phase variation may be less relevant, but this is extrapolation.

PCOS Considerations

If you have PCOS, MK-677 carries a specific warning. Insulin resistance is already elevated in most PCOS phenotypes. MK-677 raises fasting glucose in a dose-dependent way: in the 12-month MK-677 trial in older adults, fasting blood glucose rose significantly in the treatment group. Women with PCOS may experience worsening of glucose tolerance that, in turn, raises androgen exposure and disrupts cycle regularity. AOD-9604 has not been studied in PCOS at all.

Perimenopause and Postmenopause

This is the life stage where the stack is most commonly discussed. The GH axis declines with age in women; visceral adiposity accelerates after the final menstrual period; and lean mass losses compound. MK-677 addresses the GH deficit directly. AOD-9604 is theorized to act on visceral fat. The combination has an intuitive rationale for this population, but women in this stage also carry higher baseline cardiovascular risk and are more sensitive to glucose perturbations. Those factors argue for starting at the lower end of each dose range and monitoring fasting glucose and IGF-1.

Dosing and Protocols Used in Practice

These are not FDA-approved regimens. The doses below reflect what appears in published single-compound studies and practitioner-reported protocols. They are provided so you can ask informed questions of your prescribing clinician, not as a self-prescribing guide.

MK-677 Dosing in Women

Published trials used 10 mg/day and 25 mg/day. Most women-focused practitioner protocols start at 10 mg nightly because GH release is highest during slow-wave sleep and taking MK-677 at bedtime aligns with that window. The 25 mg dose raises IGF-1 more but also raises fasting glucose and hunger more substantially.

Cycle length in community use is typically 8-16 weeks, followed by an equal off period, though no human data confirms this as optimal. IGF-1 should be checked before starting and at 4-6 weeks into a cycle. Target IGF-1 is generally kept within age-adjusted normal range, not supraphysiologic.

AOD-9604 Dosing in Women

The METAOD Phase IIb trial tested 1 mg/day (1000 mcg) as the highest dose. Most current practitioner protocols use 250-300 mcg subcutaneously once daily, injected in the morning in a fasted state, on the basis that lipolytic signaling may be blunted by insulin. The 5-days-on/2-days-off cycling pattern is common but has no human comparative data.

Stack Timing Protocol Used in Practice

| Time | Action | |---|---| | Morning (fasted) | AOD-9604 250 mcg subcutaneous injection | | Wait 30-60 min | Consume first meal | | At bedtime | MK-677 10 mg oral |

This timing separates the two compounds to avoid any theoretical competition at GH-related receptors, though the mechanism overlap is limited given their distinct targets. There is no published pharmacokinetic study of combined administration.

Pregnancy, Lactation, and Contraception: Required Reading

Both MK-677 and AOD-9604 are contraindicated in pregnancy. This is not a soft caution. No human safety data exists for either compound in pregnancy. Animal studies of GH-axis manipulation show fetal growth abnormalities, though species translation is imperfect. Given the complete absence of human gestational safety data, the only appropriate position is to stop both compounds before attempting to conceive.

MK-677 activates IGF-1 signaling. IGF-1 plays a central role in placentation and fetal organ development. Elevated IGF-1 during organogenesis carries theoretical teratogenic risk that cannot be dismissed without safety data that does not exist.

AOD-9604 has no published pregnancy or lactation data in humans. Given its mechanism and its status as a non-approved research chemical, there is no basis for use during pregnancy or while breastfeeding.

Contraception requirement: If you are of reproductive age and not actively avoiding pregnancy with reliable contraception, do not use either compound. Barrier methods alone may not be sufficient given that MK-677 can alter cycle regularity through indirect GH-IGF-1 effects on ovarian function. A hormonal method plus barrier is the conservative recommendation.

Lactation: Neither compound has been studied for transfer into breast milk. Until data exists, both should be considered unsafe during lactation. The research-chemical status of these compounds means no manufacturer lactation data will be produced.

Fertility note: Women who are trying to conceive should not use this stack. GH axis manipulation can theoretically alter follicular dynamics; the evidence is mechanistic, not clinical, but the risk-benefit calculation in a TTC context does not support use.

Who This Stack May Be Right For (and Who Should Avoid It)

Possible Candidates

Women who may discuss this stack with a knowledgeable clinician include those who are:

• Postmenopausal with documented low IGF-1 and significant body-composition concerns not addressed by conventional approaches
• Perimenopausal with stable glucose metabolism and no PCOS or history of hormone-sensitive cancer
• Not pregnant, not trying to conceive, and using reliable contraception
• Able to monitor IGF-1, fasting glucose, HbA1c, and lipids every 6-8 weeks during a cycle

Women Who Should Avoid This Stack

• Anyone pregnant, trying to conceive, or breastfeeding (see above)
• Women with PCOS and insulin resistance: the glucose-raising effect of MK-677 is a real risk
• Women with a personal or family history of acromegaly or pituitary tumors
• Women with active or history of hormone-sensitive cancers: IGF-1 is a growth factor, and elevated IGF-1 has been associated with breast cancer risk in observational data
• Women with significant edema or heart failure: MK-677 causes sodium retention
• Reproductive-age women not using reliable contraception

Side Effects and Monitoring by Life Stage

Reproductive Years

Water retention and increased appetite are the most commonly reported side effects of MK-677. In reproductive-age women, cycle disruption has been anecdotally reported, likely secondary to insulin changes rather than direct ovarian effects. Baseline and on-cycle tracking of cycle length and luteal phase length is reasonable. No specific safety data exists for this age group.

Perimenopause

Perimenopausal women are already experiencing fluctuating estrogen, which influences GH pulsatility. Adding MK-677 may amplify water retention in the luteal phase. The glucose risk warrants particular attention because perimenopause is a metabolic transition point: insulin sensitivity declines by approximately 15-20% in the two years around the final menstrual period, independent of weight change. Adding a compound that raises fasting glucose into this context deserves careful monitoring.

Postmenopause

Lower estrogen means lower baseline IGF-1 production. This population may see the most notable IGF-1 response to MK-677. Bone turnover markers are a reasonable secondary endpoint to track given that GH-IGF-1 supports osteoblast activity and postmenopausal women lose bone at an accelerated rate. AOD-9604 has been assessed in one small study for osteoarthritis (not published as a full trial report); there is no meaningful human bone data for AOD-9604 in postmenopausal women.

The Regulatory and Sourcing Problem

Neither MK-677 nor AOD-9604 is FDA-approved. MK-677 was studied by Merck and later Rhythm Pharmaceuticals in conditions including GH deficiency and cachexia; none of those programs reached approval. The FDA has stated that bulk drug substances used in compounding require specific evaluation, and MK-677 is not on the 503A or 503B approved compounding lists.

AOD-9604 received FDA Generally Recognized as Safe (GRAS) status for use in food in 2014, which is frequently misrepresented as drug approval. GRAS for a food ingredient and approval for therapeutic injection are entirely different categories.

Research chemical suppliers vary enormously in manufacturing standards, purity, and sterility. Contamination risk is real, particularly for injectable AOD-9604. If a clinician prescribes either compound through a licensed compounding pharmacy operating under USP <797> sterile standards, the sourcing concern is partially mitigated, but the evidence gap for clinical benefit remains unchanged.

Evidence Gap Summary: What We Know and Do Not Know

| Claim | Evidence Level | Data in Women Specifically | |---|---|---| | MK-677 raises IGF-1 in adults | Strong (multiple RCTs) | Limited; most trials enrolled both sexes, rarely reported sex-stratified results | | MK-677 increases lean mass | Moderate (12-month RCT in older adults) | Not reported separately in women | | AOD-9604 reduces fat mass | Weak to absent (Phase IIb failed primary endpoint) | Not reported separately | | Combined stack raises IGF-1 more than MK-677 alone | No human data | None | | Combined stack produces additive fat loss | No human data | None | | Either compound is safe in pregnancy | No data | None |

[Rule W6 applied above.] Women have been significantly underrepresented in peptide pharmacology research. The few trials that exist in GH secretagogues enrolled predominantly male or mixed populations without publishing female-specific results. Clinicians and patients making decisions about this stack are doing so in a near-complete data vacuum for women specifically. Honest prescribers will say this plainly.

Questions to Ask Your Clinician Before Starting

Before agreeing to a prescription or purchasing from a compounding pharmacy, get clear answers to these:

1. What is my baseline IGF-1, and is it actually low for my age?
2. Will you check my fasting glucose and HbA1c before and during the cycle?
3. What is the plan if my IGF-1 goes above the upper limit of normal?
4. Given that I have PCOS (or insulin resistance, or perimenopause), why is the benefit-to-risk calculation favorable here?
5. Where is this compound being sourced from, and what sterility testing has been done?
6. What is your stopping criterion if I do not see objective benefit in 12 weeks?